Donanemab Slows Decline of Early Alzheimer’s

Donanemab Slows Decline of Early Alzheimer’s

Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of...
Brain discovery key to body fighting Alzheimer’s, MS

Brain discovery key to body fighting Alzheimer’s, MS

CREDIT: Dan Addison | University of Virginia Communications UVA Health researchers have discovered a molecule in the brain responsible for orchestrating the immune system’s responses to Alzheimer’s disease and multiple sclerosis (MS), potentially allowing doctors to...
Alzheimer’s may not be chiefly a brain disease

Alzheimer’s may not be chiefly a brain disease

The pursuit of a cure for Alzheimer’s disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies. In July 2022, Science magazine reported that a key 2006 research paper, published in the...